September 2025 – Kinstellar has successfully advised GTCR, a leading US-based private equity firm, on its agreement to acquire Zentiva, a prominent European generics pharmaceutical company, from global private equity investor Advent International. The transaction marks one of the most significant healthcare buyouts in Europe this year and is expected to close in early 2026, subject to customary regulatory approvals.
Kinstellar acted as local counsel to GTCR, providing full-scope legal support across Central and Eastern Europe, including corporate, regulatory, and transactional matters. The firm collaborated closely with Kirkland & Ellis, GTCR's lead legal advisor, on this high-profile cross-border deal. Under Advent's ownership since 2018, Zentiva has undergone a major transformation, expanding its portfolio, manufacturing capacity, and market presence, with revenue and EBITDA more than doubling over the investment period.
The Kinstellar team was led by Partner Jan Juroaka, with support from Tomáa Čihula, Adam Němec, Martina Mazůrková, Michal Jandus and Jakub Rubáa. In Romania, the team was led by Rusandra Sandu, supported by Cristina Stamboli, Andrada Popescu, Denisa Constantin, Alexandru Dan, Luiza Bedros and Marc Barabas. In Slovakia, the team included Dominika Bajzáthová, Adam Pichler, Matúa Kočíaek and Alexandra Milde.